Standard treatments for heart disease focus heavily on lowering cholesterol in the bloodstream. But what if the problem isn’t just floating in your blood, but trapped deep inside the cells of your heart and artery walls?
Recent research from Osaka University suggests that for a specific subset of patients, a simple dietary supplement may offer a way to “unclog” arteries from the inside out. The findings, published in the European Heart Journal, highlight a distinct and often overlooked form of heart disease that does not respond to conventional therapies like statins or stents.
The Hidden Culprit: TGCV
Coronary artery disease (CAD) is typically associated with atherosclerosis —the buildup of cholesterol-rich plaque that narrows arteries and restricts blood flow. However, researchers in Japan have identified a different mechanism called triglyceride deposit cardiomyovasculopathy (TGCV).
Unlike classic atherosclerosis, TGCV is driven by the accumulation of triglycerides (a type of fat) inside the smooth muscle cells of the heart and blood vessel walls. This occurs due to a defect in how cells break down fat internally.
“Almost 15 years ago, we identified a new type of CAD… in which the coronary arteries are occluded by triglyceride deposits generated by defective intracellular breakdown of triglycerides,” said lead author Ken-ichi Hirano. “This mechanism makes TGCV distinct from classic cholesterol-induced atherosclerosis.”
Why this matters:
* Undiagnosed Risk: TGCV is particularly common in patients with diabetes mellitus and those undergoing hemodialysis.
* Treatment Resistance: Because the root cause is intracellular fat buildup rather than blood cholesterol, standard cholesterol-lowering drugs often fail to provide relief for these patients.
The Tricaprin Intervention
The Osaka University team investigated tricaprin, a commercially available dietary supplement known to stimulate fat metabolism (lipolysis) in heart muscle cells. The study focused on two patients in their 60s who suffered from:
1. Diabetes mellitus.
2. Severe, persistent chest pain.
3. Coronary artery disease that had not improved with standard treatments.
After being diagnosed with TGCV, both patients began taking tricaprin regularly. The results were striking:
- Symptom Relief: Both patients reported significant improvement in chest pain within months.
- Visible Artery Changes: Follow-up imaging scans showed a reduction in triglyceride buildup and a widening of previously narrowed blood vessels.
- Cellular Activity: Researchers observed increased fat breakdown activity within the heart tissue itself.
Crucially, these improvements occurred without major changes in standard blood lipid measurements. This suggests that tricaprin worked through a completely different biological pathway than traditional cholesterol-lowering therapies.
A New Concept in Cardiology
Cardiologists have long understood that aggressively lowering serum lipids can sometimes slow or partially reverse plaque buildup. However, the Osaka team argues that this case represents a fundamentally different approach.
“While atherosclerosis regression following decreased serum lipid levels is well-described, this is the first report of regression due to increased triglyceride lipolysis within cells,” Hirano stated. “As such, it is a conceptually novel treatment for coronary atherosclerosis.”
This distinction is significant because it points toward a potential treatment strategy for patients who are “treatment-resistant”—those who do not improve with statins, stents, or other conventional interventions aimed primarily at blood cholesterol.
Caution and Future Research
While the results are promising, scientists emphasize that this is an early-stage finding. The original report involved only two patients, which is insufficient to establish tricaprin as a mainstream therapy.
- Clinical Trials: Research is ongoing. A Phase IIa clinical trial in Japan is currently evaluating CNT-01 (a formulation of tricaprin/trisdecanoin) in patients with idiopathic TGCV.
- Medical Supervision: Experts warn that patients should not replace prescribed cardiac medications with supplements without consulting their doctors.
Conclusion
The work from Osaka University suggests that the future of heart disease treatment may need to look beyond cholesterol in the bloodstream. By targeting how fat is processed deep inside the cells of the heart, researchers may unlock new therapies for patients with treatment-resistant forms of coronary artery disease. While more large-scale studies are needed, these findings offer hope for a complex condition that has long been misunderstood.
